Learn More
One of the objectives in the development of effective cancer therapy is induction of tumor-selective cell death. Toward this end, we have identified a small peptide that, when introduced into cells via a TAT cell-delivery system, shows a remarkably potent cytoxicity in a variety of cancer cell lines and inhibits tumor growth in vivo, whereas sparing normal(More)
  • G Gaidos, R A Lewis, G A Smith, B Dundore, S Chakrabarti
  • 1999
Production and trapping of small numbers of antiprotons for space applications are reviewed, setting the stage for antiproton-catalyzed microfission/fusion (ACMF) reactions as a source of propulsive power. A spacecraft designed around an ACMF engine has been designed. Details, including Isp, thrust, structural features, power systems, radiation shields, ion(More)
Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors (DR4 and DR5) are currently being created for clinical cancer therapy, due to their selective killing of cancer cells and high safety characteristics. However, resistance to TRAIL and other targeted therapies is an important issue facing current cancer research field. An attractive(More)
Overexpression of the cellular FLICE-like inhibitory protein (cFLIP) has been reported in a number of tumor types. As an inactive procaspase-8 homologue, cFLIP is recruited to the intracellular assembly known as the Death Inducing Signaling Complex (DISC) where it inhibits apoptosis, leading to cancer cell proliferation. Here we characterize the molecular(More)
  • 1